Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonu ...
A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuva ...
Phenylketonuria;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Kuvan 100mg soluble tablet Product Name: Sapropterin Dihydrocholoride